Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q99963
UPID:
SH3G3_HUMAN
Alternative names:
EEN-B2; Endophilin-3; SH3 domain protein 2C; SH3 domain-containing GRB2-like protein 3
Alternative UPACC:
Q99963; O43553; O43554
Background:
Endophilin-A3, known by alternative names such as EEN-B2, Endophilin-3, SH3 domain protein 2C, and SH3 domain-containing GRB2-like protein 3, plays a crucial role in endocytosis. It is believed to recruit other proteins to membranes with high curvature, showcasing its importance in cellular processes.
Therapeutic significance:
Understanding the role of Endophilin-A3 could open doors to potential therapeutic strategies. Its involvement in fundamental cellular processes highlights its potential as a target for drug discovery efforts aimed at treating diseases where endocytosis is implicated.